Advances in Motion provides health care professionals with information about the latest breakthroughs, research and clinical advances from Massachusetts General Hospital.
EXPLORE OUR SPECIALTIES BROWSE OUR TOPICS SUBSCRIBE TO RECEIVE UPDATES
Featured In Rheumatology, Allergy and Immunology
Mass General Program One of the Few in the World to Focus on Vasculitis Patients
Sebastian Unizony, MD, and Zachary S. Wallace, MD, MSc, co-directors of the Vasculitis Program at Massachusetts General Hospital, discuss the program's multidisciplinary approach to care and pioneering research efforts.
Featured In Orthopaedics
Inferior Screw Placement Drastically Improves Revision THA Outcomes
Massachusetts General Hospital researchers have determined that inferior screw fixation drastically reduces failure after revision total hip arthroplasty.
Featured In Otolaryngology
CRISPR-Cas9 Genome Editing Treats Genetic Hearing Loss by Promoting Outer Hair Cell Survival
Yong Tao, PhD, Veronica Lamas, PhD, and Zheng-Yi Chen, DPhil, have extended their previous murine research to show CRISPR-associated protein 9 (Cas9)-based genome editing can treat hearing loss associated with monogenic mutations in outer hair cell genes and digenic mutations affecting both inner and outer hair cells.
Featured In Neuroscience
Developing Noninvasive Methods to Effectively Treat Complex Brain Disorders
Research at Massachusetts General Hospital combines advanced neuroimaging techniques and noninvasive brain stimulation to drive precision medicine for neurological disorders.
Featured In Urology
Less Aggressive Protocol Suitable for Muscle-invasive Bladder Cancer in Noncystectomy Candidates
Douglas M. Dahl, MD, Jason A. Efstathiou, MD, DPhil, and colleagues determined that in patients with muscle-invasive bladder cancer who were not candidates for cystectomy or cisplatin, maximum tumor resection and chemoradiation were associated with high response rates and five-year overall survival rates of 25% to 38%.
The Latest Digestive Health Advances
AGA Guideline Makes the Case for Biomarkers in Managing Crohn's Disease
Ashwin Ananthakrishnan, MD, discusses the AGA guideline's key recommendations for managing Crohn's disease and the evolving role of biomarkers in these treatments.
Fatigue in Inflammatory Bowel Disease Linked to Substantial Economic Burden
Ashwin N. Ananthakrishnan, MBBS, MPH, and colleagues found that healthcare resource utilization was significantly higher for inflammatory bowel disease (IBD) patients with fatigue than those without. The same was true for IBD-related and all-cause medical and pharmacy costs, regardless of IBD subtype or severity.
Contributing Physicians
Ashwin N. Ananthakrishnan, MBBS, MPH
Director of the Crohn's and Colitis Center, Division of Gastroenterology, Mass General, Associate Professor of Medicine, Harvard Medical School
Kathleen E. Corey, MD, MPH, MMSc
Director, Fatty Liver Clinic, Mass General Gastrointestinal Unit, Associate Professor of Medicine, Harvard Medical School
Advances Specialties
Neuroscience
Essential Tremor Treatment Advancements Using MRI-guided Focused Ultrasound: Q&A With Jeffrey S. Schweitzer, MD, PhD
Jeffrey S. Schweitzer, MD, PhD, a neurosurgeon at Massachusetts Hospital, specializing in treating epilepsy, essential tremor, and tremor-dominant Parkinson's diseases. In this Q&A, Dr. Schweitzer discusses the physiological processes underlying essential tremor and the advancements.
OB/GYN
Comprehensive Lymphadenectomy Often Not Necessary in Surgical Management of Primary Endometrioid Ovarian Carcinoma
Varvara Mazina, MD, Marcela G. del Carmen, MD, MPH, and colleagues showed in a retrospective cohort of 63 women with primary endometrioid ovarian cancer that all pelvic and para-aortic lymph nodes removed were negative for carcinoma and comprehensive cancer staging had no effect on progression-free or overall survival.
Oncology
Revolutionizing Cancer Immunotherapy for Melanoma and Beyond
Researchers at Massachusetts General Hospital won a Breakthrough Award to enhance personalized approaches to immunotherapy for metastatic melanoma.
May 10, 2024
Conference: Midlife Women's Health 2024: A Multidisciplinary Approach to Care
The Midlife Women's Health 2024 course is led by a multidisciplinary group of experts from Massachusetts General Hospital who will present on the evaluation and management of gynecologic cancers, cardiovascular health, menopausal hormone therapy, ADHD, sexuality after cancer, and more to assist clinicians in caring for their midlife patients. The entire program will be available to registrants for 30 days after the event, with CME credit provided only to those who log in on the day of the conference.
April 13-18, 2024
Conference: AAN 2024: The American Academy of Neurology Annual Meeting
Neurology leaders from Massachusetts General Hospital will present their latest research at the American Academy of Neurology (AAN) 2024 Annual Meeting. This hybrid event takes place both in-person in Denver, CO, and virtually on April 13–18, 2024.
